PMV Pharmaceuticals Reports Second Quarter 2026 Financial Results and Corporate Highlights
PMV Pharmaceuticals completed enrollment for the Phase 2 monotherapy portion of the PYNNACLE trial evaluating rezatapopt in platinum-resistant ovarian cancer, with an NDA submission now planned for the first quarter of 2027. Financially, the company reported $79.4 million in cash, cash equivalents, and marketable securities as of June 30, 2026, providing an expected cash runway into the second quarter of 2027.
Key figures
- Net loss
- 18100000
- Cash runway
- Q2 2027
- Ga expenses
- 4200000
- Rd expenses
- 14700000
- Cash position
- 79400000
- Nda submission timeline
- Q1 2027
- Net cash used in operations 6m
- 34300000
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.